Stocks and Investing Stocks and Investing
Thu, November 30, 2023

Michael Ulz Maintained (ARWR) at Hold with Decreased Target to $37 on, Nov 30th, 2023


Published on 2024-10-28 07:47:54 - WOPRAI, Michael Ulz
  Print publication without navigation


Michael Ulz of Morgan Stanley, Maintained "Arrowhead Pharmaceuticals, Inc." (ARWR) at Hold with Decreased Target from $40 to $37 on, Nov 30th, 2023.

Michael has made no other calls on ARWR in the last 4 months.



There are 4 other peers that have a rating on ARWR. Out of the 4 peers that are also analyzing ARWR, 1 agrees with Michael's Rating of Hold. Following is the relevant analyst calls for the last 4 months


  • Shawn Egan of "Citigroup" Initiated at Hold and Held Target at $33 on, Tuesday, September 19th, 2023


These are the ratings of the 3 analyists that currently disagree with Michael


  • Patrick Trucchio of "HC Wainwright & Co." Reiterated at Strong Buy and Held Target at $90 on, Wednesday, August 9th, 2023
  • Alethia Young of "Cantor Fitzgerald" Maintained at Buy with Decreased Target to $47 on, Tuesday, August 8th, 2023
  • Keay Nakae of "Chardan Capital" Reiterated at Strong Buy and Held Target at $60 on, Tuesday, August 8th, 2023
Contributing Sources